Yield of Recommended Blood Tests for Neonates Requiring Phototherapy for Hyperbilirubinemia

Itay Besser MD1, Zvi H. Perry MD MA2,3, Oded Mesner MD1, Ehud Zmora MD1 and Asaf Toker MD MHA4

Departments of 1 Neonatology and 2 Surgery, Soroka University Medical Center, Beer Sheva, Israel
3Department of Epidemiology and Health Services Evaluation, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Hospital Management, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel

ABSTRACT: Background: Hyperbilirubinemia of the newborn is common. Rarely is an underlying disease other than physiologic hyperbilirubinemia considered the cause of high bilirubin levels. Some of the laboratory tests recommended by the American Academy of Pediatrics are expensive and do not always lead to diagnosis.

Objective: To evaluate the efficacy of standard laboratory tests performed on newborn infants requiring phototherapy for hyperbilirubinemia.

Methods: We conducted a retrospective chart review that included neonates born during a 6 month period with birth weight > 2500 g treated with phototherapy for hyperbilirubinemia (n=282) according to published guidelines. The main outcome measures were primary and maximal bilirubin values (mg/dl), time to jaundice (in days), the number of bilirubin tests undertaken and whether the patient showed abnormal functioning, and the number of days in follow-up.

Results: Thirty-three neonates (11.7%) were positive in at least one laboratory test (defined as “Abnormal” in our study), 45.5% of whom met the criteria for phototherapy during the first 48 hours of life. Among the newborns who were negative for all laboratory tests (defined as “Normal”), only 6.8% met phototherapy criteria within their first 48 hours of life (P < 0.001). In the Normal group there was a consistent decrease in total serum bilirubin values shortly after phototherapy was begun, while the Abnormal group presented an increase in serum bilirubin values during the first 12 hours of phototherapy. None of the infants had conjugated (direct) hyperbilirubinemia during the study period.

Conclusions: Most neonates presenting with a laboratory identifiable etiology for hyperbilirubinemia (i.e., hemolysis) can be distinguished from those who test negative, mainly based on the timing of presentation and response to phototherapy. A more meticulous selection of patients and reduction in the magnitude of routine laboratory testing can safely reduce discomfort to infants with hyperbilirubinemia as well as costs.

KEY WORDS: neonatal hyperbilirubinemia, cost, phototherapy

Neonatal hyperbilirubinemia is diagnosed when the total serum bilirubin is higher than accepted with respect to weight and age of the newborn. According to the American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in infants of ≥ 35 weeks gestation, if a newborn requires phototherapy the following laboratory evaluation is recommended to detect the hyperbilirubinemia etiology [1,2]: TSB or transcutaneous bilirubin, neonate’s blood type and direct Coombs test (if not already performed on cord blood), complete blood count and smear, direct/conjugated bilirubin level, glucose 6-phosphate dehydrogenase activity or end-tidal CO2 measurement as an option, and measurement of TSB level every 4–24 hours depending on the neonate’s age and TSB level. When TSB level approaches the need for exchange transfusion or when the newborn is unresponsive to phototherapy, the following tests are recommended: reticulocyte count, G6PD activity profile, albumin level, and end-tidal CO2 if available.

Newman et al. [3] found that most of the laboratory workup for determining the etiology for hyperbilirubinemia is futile. Most laboratory tests have poor sensitivity and specificity, and rarely is an underlying disease other than physiologic hyperbilirubinemia considered the cause of high levels of bilirubin severe enough to meet criteria of phototherapy. According to their study, only blood type (of mother and neonate) and direct Coombs test are obligatory. They concluded that there is no value in measuring direct bilirubin, unless jaundice persists for 2–4 weeks.

Bilirubin toxicity is rare in the absence of hemolysis; therefore, if there is no hemolysis, the risk, cost and discomfort of further evaluation for hyperbilirubinemia may outweigh the benefit. It has been demonstrated that most of the laboratory tests recommended by the AAP are expensive and rarely lead to a diagnosis other than ABO incompatibility or Rh isoimmunization. Moreover, if hemolysis did occur, it may coexist with other etiologies such as Streptococcus group B bacteremia [4].


TSB = total serum bilirubin
G6PD = glucose 6-phosphate dehydrogenase
AAP = American Academy of Pediatrics
found that when those tests are done as part of hemolysis screening in hyperbilirubinemic neonates, the diagnosis of hemolysis is rarely made in conditions other than isoimmunization. That study also demonstrated that if a direct Coombs test is positive there is no need to conduct other laboratory tests, and if the test is negative a full laboratory workup is required only for neonates in whom other reasons for hemolysis are suspected, such as a family history of red blood cell dysfunction [5].

During the period of our research, when a newborn met the criteria for phototherapy, a routine battery of laboratory tests was performed in some cases, including G6PD activity qualitative screen, blood type, direct Coombs test, complete blood count, reticulocyte count, total and direct bilirubin, and liver function tests. The tests were performed to establish the cause of severe hyperbilirubinemia. Our main objective was to assess the efficacy of the screening tests in evaluating significant neonatal hyperbilirubinemia requiring phototherapy in our institute.

**PATIENTS AND METHODS**

We conducted a retrospective study, using data from the medical charts of neonates who were born and hospitalized in Soroka Medical Center in Beer Sheva, Israel, for 6 months and treated with phototherapy due to jaundice during their first month of life. The overall number of births in our tertiary medical center during the research year reached 13,000, of which 7474 occurred within the study period. A total of 282 neonates required phototherapy, an incidence of 3.8%. Newborn medical charts were selected according to our inclusion criteria (i.e., birth weight ≥ 2500 g and phototherapy).

The recorded data included details such as gender and ethnicity, gestational age, birth weight, blood type, age upon discharge, mode of delivery, relevant medical history, bilirubin values (first, maximal, and upon discharge), number of capillary bilirubin tests, and time under phototherapy. Laboratory evaluation comprised complete blood count, blood cultures and electrolytes and liver functions including total and direct bilirubin, direct Coombs test and qualitative G6PD activity test. Other data included number of readmissions 30 days after discharge and number of follow-up days.

Our study design was approved by the Helsinki Subcommittee for trials in human subjects at the Soroka Medical Center (research # 4078).

**STATISTICAL ANALYSIS**

Statistical analysis was performed using SPSS (Statistical Package for Social Sciences) for Windows 14.0 (Chicago, IL, USA). Average and standard deviations were used for comparisons of data, and parametric tests (paired t-test, independent t-test) and non-parametric tests (Mann-Whitney and chi-square tests) when applicable. 
P values < 0.05 with confidence interval of 95% were considered statistically significant.

**RESULTS**

Altogether, 282 newborn infants were found suitable for phototherapy during the study period; of these, 181 (64.2%) were male, 186 (66%) were Jewish and 96 (34%) were Muslim Arabs. Regarding mode of delivery, 215 (76.2%) were delivered vaginally, 59 (20.9%) by cesarean section and 8 (2.8%) by vacuum extraction. The average length of pregnancy was 38.25 weeks (± 1.74), with an average birth weight of 3179.2 g (± 460.3); 51 (18%) were born < 37 weeks.

With regard to blood type, 48.6% of the mothers (137 mothers) were O+, while 30.5% (85) of the newborns were A+ blood type; 156 mothers (55.3%) were either blood type O or Rh-.

The average postnatal age of babies beginning phototherapy was 4.7 ± 2.53 days. Average postnatal age upon discharge was 7 days; mean duration of admission was 6.7 ± 3.19 days. Mean bilirubin value at the start of phototherapy reached 16.6 mg/dl, and the mean maximal recorded value was 18.4 ± 2.63 mg/dl; the mean value upon discharge was 12.6 ± 2.18 mg/dl.

**LABORATORY TEST DATA**

The mean number of specific bilirubin tests was 9.7 ± 5.5 per neonate with a maximum of 34 tests; the average time under phototherapy was 38.15 ± 21.94 hours with a maximum of 132 hours. All other laboratory tests are described in Table 1a.

Neonates positive for at least one of the laboratory tests (direct Coombs test, reticulocyte count, and G6PD deficiency) were male, 186 (66%) were Jewish and 96 (34%) were Muslim Arabs. Regarding mode of delivery, 215 (76.2%) were delivered vaginally, 59 (20.9%) by cesarean section and 8 (2.8%) by vacuum extraction. The average length of pregnancy was 38.25 weeks (± 1.74), with an average birth weight of 3179.2 g (± 460.3); 51 (18%) were born < 37 weeks.

With regard to blood type, 48.6% of the mothers (137 mothers) were O+, while 30.5% (85) of the newborns were A+ blood type; 156 mothers (55.3%) were either blood type O or Rh-.

The average postnatal age of babies beginning phototherapy was 4.7 ± 2.53 days. Average postnatal age upon discharge was 7 days; mean duration of admission was 6.7 ± 3.19 days. Mean bilirubin value at the start of phototherapy reached 16.6 mg/dl, and the mean maximal recorded value was 18.4 ± 2.63 mg/dl; the mean value upon discharge was 12.6 ± 2.18 mg/dl.

**Table 1a. Laboratory evaluation performed at start of phototherapy**

<table>
<thead>
<tr>
<th>Test</th>
<th>No. of tests</th>
<th>Mean result***</th>
<th>No. of newborns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver function tests (mg/dl)*</td>
<td>271</td>
<td>16.8 (± 3.8)</td>
<td>100% of tests showed direct/total ratio &lt; 0.2</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td></td>
<td>0.88 (± 0.2)</td>
<td></td>
</tr>
<tr>
<td>Direct bilirubin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood type</td>
<td>240</td>
<td></td>
<td>136 (56.7%)</td>
</tr>
<tr>
<td>No incompatibility</td>
<td></td>
<td></td>
<td>104 (43.3%)</td>
</tr>
<tr>
<td>Incompatibility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reticulocyte count</td>
<td>236</td>
<td>4.05% (± 2.8)</td>
<td>Reticulocytosis was found in 9 newborns (3.8%)**</td>
</tr>
<tr>
<td>Direct Coombs test</td>
<td>282</td>
<td>20 (7.1%)</td>
<td></td>
</tr>
<tr>
<td>G6PD activity</td>
<td>282</td>
<td>7 (2.5%)</td>
<td>showed zero activity</td>
</tr>
<tr>
<td>Liver function test</td>
<td>42</td>
<td>59 U/L (± 33.16)</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td></td>
<td>34 U/L (± 28.75)</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood culture</td>
<td>48</td>
<td>3 (6.4%)</td>
<td>were positive</td>
</tr>
</tbody>
</table>

* Liver functions tests includes direct and total bilirubin
** > 10% reticulocytes defined as reticulocytosis
*** Values in brackets represent standard deviation
AST = aspartate aminotransferase, ALT = alanine aminotransferase
Of all 282 neonates, 33 (11.7%) were found positive for at least one of the tests and were defined as "Abnormal" in our study. The remaining 249 (88.3%) were found negative in all laboratory tests and as such were defined as "Normal." There were no significant statistical differences between the two groups regarding demographics (gender and ethnicity), birth weight, gestational age, and blood type of mother and newborn.

Direct and total bilirubin values were not used as distinguishing factors between the two groups since 100% of liver function tests yielded direct/total bilirubin ratios less than 20%, suggesting there was no evidence for direct hyperbilirubinemia during the study period. Reticulocyte count above 20%, suggesting there was no evidence for direct hyperbilirubinemia, was prevalent in all tests. Direct/total bilirubin ratio was not used as distinguishing factors between the two groups since 100% of liver function tests yielded direct/total bilirubin ratios less than 20%. There was no evidence for direct hyperbilirubinemia (≥ the 95th percentile according to the Bhutani nomogram [6]). Although jaundice is common and is usually physiologic in nature, it can represent a pathologic process or a complication. Clinically apparent jaundice can be seen in as many as 60% of all term newborns during the first week of life. However, it was previously observed that most of the laboratory workup conducted while searching for the cause of hyperbilirubinemia does not help establish a diagnosis. The sensitivity and specificity of these tests are poor, and rarely is an underlying disease (other than physiologic hyperbilirubinemia) considered the cause of a bilirubin level high enough to require phototherapy [7-9].

Neonates are discharged from Israeli hospitals 36–48 hours after delivery, limiting our ability to screen for and diagnose hyperbilirubinemia in the newborn. Therefore, the need for phototherapy has become a leading cause for readmission. It has been established that if a direct Coombs test is positive there is no need for other laboratory tests, and even if the result is negative a full laboratory workup is indicated only for neonates in whom there is a reason to suspect other causes for hemolysis such as anemia, early jaundice, or familial history of red blood cell dysmorphism.

A comparative analysis of three strategies for screening and prevention of kernicterus in the newborn did not demonstrate any benefit of conducting a full laboratory workup to detect and prevent one incident of kernicterus [10-12]. Regarding phototherapy, the AAP guidelines state that if TSB level does not decrease, or continues to rise despite proper phototherapy, there is a reasonable basis to suspect hemolysis. It can be concluded that if bilirubin level decreases

---

### Table 1b. Differences between the two groups during hospital stay

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Abnormal</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of stay (days)*</td>
<td>6.5 (± 2.62)</td>
<td>7.6 (± 6.02)</td>
<td>0.339</td>
</tr>
<tr>
<td>Age at discharge (days)*</td>
<td>6.6 (± 2.618)</td>
<td>7.7 (± 5.988)</td>
<td>0.323</td>
</tr>
<tr>
<td>Onset of phototherapy (days)*</td>
<td>5 (± 2.51)</td>
<td>2.5 (± 1.35)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Bilirubin value (mg/dl)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial</td>
<td>17.7 (± 2.73)</td>
<td>14 (± 3.8)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Maximal</td>
<td>18.3 (± 2.59)</td>
<td>17.5 (± 2.5)</td>
<td>0.129</td>
</tr>
<tr>
<td>Number of bilirubin tests*</td>
<td>10 (± 5.57)</td>
<td>12 (± 4.77)</td>
<td>0.063</td>
</tr>
<tr>
<td>Hours under phototherapy*</td>
<td>38.8 (± 22.5)</td>
<td>49.9 (± 30.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>Direct/total bilirubin ratio*</td>
<td>&lt; 0.2 in all tests</td>
<td>&lt; 0.2 in all tests</td>
<td>–</td>
</tr>
<tr>
<td>Hemoglobin level (mg/dl)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial</td>
<td>18.5 (± 2.28)</td>
<td>15.8 (± 3.1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Second</td>
<td>18.9 (± 2.54)</td>
<td>14.9 (± 3.76)</td>
<td>0.02</td>
</tr>
<tr>
<td>Blood count results**</td>
<td>8.6% positive</td>
<td>0% positive</td>
<td>0.338</td>
</tr>
<tr>
<td>Liver function tests (U/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>60 (± 35.6)</td>
<td>45 (± 28.24)</td>
<td>0.211</td>
</tr>
<tr>
<td>ALT</td>
<td>30 (± 28.13)</td>
<td>37 (± 35.3)</td>
<td>0.653</td>
</tr>
<tr>
<td>Discharge with follow-up**</td>
<td>38%</td>
<td>69%</td>
<td>0.001</td>
</tr>
</tbody>
</table>

* Statistical analysis using Independent samples t-test
** Statistical analysis using chi-square test

AST = aspartate aminotransferase, ALT = alanine aminotransferase

### DISCUSSION

Hyperbilirubinemia of the newborn is defined as TSB levels ≥ the 95th percentile according to the Bhutani nomogram [6]. Although jaundice is common and is usually physiologic in nature, it can represent a pathologic process or a complication. Clinically apparent jaundice can be seen in as many as 60% of all term newborns during the first week of life. However, it was previously observed that most of the laboratory workup conducted while searching for the cause of hyperbilirubinemia does not help establish a diagnosis. The sensitivity and specificity of these tests are poor, and rarely is an underlying disease (other than physiologic hyperbilirubinemia) considered the cause of a bilirubin level high enough to require phototherapy [7-9].

Regarding phototherapy, the AAP guidelines state that if TSB level does not decrease, or continues to rise despite proper phototherapy, there is a reasonable basis to suspect hemolysis. It can be concluded that if bilirubin level decreases
under phototherapy, there is no reason to suspect hemolysis as the cause of the hyperbilirubinemia.

To date, the question of whether to perform a full laboratory evaluation immediately after starting phototherapy or to wait a few hours, observe the pattern of bilirubin levels under phototherapy, and then conduct the recommended laboratory tests if necessary has not been sufficiently studied. One of our main objectives was to consider the necessity of performing all the recommended tests at the beginning of phototherapy, searching for direct hyperbilirubinemia or hemolysis, or wait for a few hours and widen our investigation depending on the response of bilirubin values to phototherapy. The incidence of phototherapy among newborns weighing > 2500 g in our study was 4%; 11.7% of them were found positive for at least one of the tests, defined as Abnormal, while those who were found negative to all tests were referred to as Normal.

All 271 liver function tests showed a direct/total bilirubin ratio of less than 0.2, meaning all newborns who required phototherapy and underwent liver function tests presented with indirect hyperbilirubinemia.

In the Abnormal group 45.5% began phototherapy during the first 48 hours of life compared to only 6.8% in the Normal group (P < 0.001). We can therefore conclude that if early jaundice is present (< 48 hours from delivery) and the newborn requires phototherapy, further laboratory workup is recommended since the chance of encountering hemolysis is high. That notion fits the definition of a screening test, known to be more efficient in populations at risk than in the general population. When we compared the pattern of bilirubin values during the first 24 hours under phototherapy, we found that although the Abnormal group started phototherapy with lower bilirubin values (because jaundice is apparent earlier in life among hemolytic newborns), the pattern of bilirubin values also differed from that of Normal neonates. While the Abnormal group presented with an increase in bilirubin values during the first 12 hours of phototherapy, followed by a plateau between 12 and 18 hours and a decrease after 18 hours, the Normal group showed a consistent decrease immediately after starting phototherapy [Figure 2].

Therefore, it can be concluded that if jaundice is not evident early in the neonate’s life and the newborn requires phototherapy, establishing the etiology of hyperbilirubinemia during the first few hours of phototherapy can be avoided. If bilirubin levels continue to decline there is no reason to try to establish the cause (since in this case jaundice is probably physiologic in nature). But if values do increase (or stay the same) it is feasible to expand the laboratory evaluation [Figure 3].

Our results also showed that only 65% of all blood type tests were justifiable because only 156 of the mothers had either O blood type or Rh-negative factor. To date, every jaundiced neonate who starts phototherapy is screened for blood type, regardless of the mother’s blood type. Forty-two liver function tests were performed with no indication according to medical charts; all were found normal.

The study has several limitations. The study period was 7 months, which means that the yearly incidence of hyperbilirubinemic neonates requiring phototherapy could only be extrapolated from our results. Among the 33 newborns who were defined as Abnormal, only 20 capillary bilirubin tests were documented at 24 hours; if more tests had been documented at 24 hours, the curve for the abnormal group in Figure 2 might have shown continuance of a plateau or even an increase in bilirubin levels instead of a decline (as presented).

** Table 1a. Laboratory evaluation performed upon starting phototherapy

<table>
<thead>
<tr>
<th>Need for phototherapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 48 hours</td>
</tr>
<tr>
<td>Age ≤ 48 hours</td>
</tr>
</tbody>
</table>

1. Perform laboratory evaluation:
   - Complete blood count including reticulocyte count**
   - Qualitative G6PD activity test**
   - Direct Coombs test
   - Newborn’s blood type if mother carries type O or is Rh-
   - Consider total and direct bilirubin test***
2. Measure bilirubin level every 4–8 hours

* According to AAP guidelines.
** Reticulocyte count and qualitative G6PD activity test are performed if the newborn is not responsive to phototherapy or when TSB level approaches the need for exchange transfusion.
*** Study results showed the yield of total and direct bilirubin to be extremely low (if any) for detecting direct hyperbilirubinemia.
CONCLUSIONS

According to our findings there is no financial or clinical benefit in conducting a full laboratory evaluation (according to AAP guidelines) to identify possible causes of severe hyperbilirubinemia in neonates found suitable for phototherapy, unless the jaundice was early (< 48 hours from birth). Neonates presenting with non-physiologic jaundice (i.e., hemolysis) based on laboratory results, can be distinguished from those who develop physiologic jaundice, according to the pattern of bilirubin values during the first 18 hours under phototherapy.

If early jaundice is diagnosed (< 48 hours from birth), we recommend a full laboratory evaluation at the start of phototherapy (by indication) because the chance of detecting hemolysis at this age is high. Given that the yield of direct and total bilirubin in detecting direct hyperbilirubinemia is very low, one should reconsider its relevance in the laboratory workup while searching for causes of hyperbilirubinemia in neonates.

Correspondence:
Dr. A. Toker
Hospital Management, Schneider Children’s Medical Center of Israel, Petah Tikva 49292, Israel
Phone: (972-3) 925-3600
email: asaf.to@clalit.org.il

References

Capsule

The immune response during acute HIV-1 infection

The early immune response to human immunodeficiency virus-1 (HIV-1) infection is likely to be an important factor in determining the clinical course of disease. Recent data indicate that the HIV-1 quasispecies that arise following a mucosal infection are usually derived from a single transmitted virus. Moreover, the finding that the first effective immune responses drive the selection of virus escape mutations provides insight into the earliest immune responses against the transmitted virus and their contributions to the control of acute viremia. Strong innate and adaptive immune responses occur subsequently but they are too late to eliminate the infection. In a review, McMichael et al. discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine.

Eitan Israeli

Capsule

Transmission of drug resistance

Understanding the dynamics of drug-resistant strains of human immunodeficiency virus (HIV) and the key determinants affecting their evolution and spread is crucial for predicting future effects of drug treatment. Current models can only track one resistant strain, so Smith and team used empirical data from San Francisco to parameterize models that consider the transmission of single-, double-, and triple-resistant HIV strains. Many people who are infected with a resistant strain are capable of infecting more than one other person – a scenario that could trigger an epidemic wave of drug-resistant virus. At a time when the WHO’s strategy for universal testing and treatment is being rolled out, the insights gained from this work are not restricted to HIV transmission and treatment in resource-rich countries, but are widely applicable.

Science 2010; 327: 697
Eitan Israeli